Semaglutide
The sentences below are limited to one FDA page opened for this draft.
What the opened sources say
Section titled “What the opened sources say”- FDA names semaglutide among GLP-1 receptor agonist drugs for which people seek unapproved versions, and says those versions are not reviewed for safety, effectiveness, and quality before marketing.
- FDA says some compounders have sold semaglutide sodium and semaglutide acetate. It says those salts are different active ingredients from the approved drugs and that it knows of no lawful basis to use them in compounding.
- FDA says it is aware of counterfeit Ozempic marketed in the United States. This page does not describe the approved product’s indications or dose.
- As of 31 May 2026, FDA says it had received 990 adverse-event reports associated with compounded semaglutide. It says it is not always possible to tell whether the drug caused the event.
- FDA says it has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, from patients measuring incorrect doses and from clinicians miscalculating doses.
Not stated here
Section titled “Not stated here”Specific finished products that contain semaglutide have been discussed by FDA as GLP-1 drugs. This page does not list application numbers.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
- Cagrilintide
- GLP-1 receptor agonists
- Mazdutide
- Peptide synthesis notes
- Peptides
- Retatrutide
- Survodutide
- Tirzepatide
A link from another wiki page is not evidence. Facts should point at the sources above.